Phase I and Clinical Pharmacology Study of Intravenous Flavone Acetic Acid (NSC 347512)

Cancer Research

Volumn 48, Issue 20, 1988, Pages 5878-5882

  Weiss, Raymond B ^a,c   Greene, Raymond F ^b   Knight, Robert D ^a,c   Collins, Jerry M ^b   Pelosi, John J ^a   Sulkes, Aaron ^b   Curt, Gregory A ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOFLAXONE;

AGE; ASTHENIA; CANCER PATIENT; CLINICAL ARTICLE; DRUG THERAPY; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; BLOOD PRESSURE; DRUG EVALUATION; FEMALE; FLAVONES; HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGE; NEOPLASMS;

EID: 0023712232     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Atassi, G., Briet, P., Berthelon, J.-J., and Collonges, F. Synthesis and antitumor activity of some 8-substituted-4-oxo-4H-1-benzopyrans. Eur. J. Med. Chem., 20: 393-402, 1985.
2. Plowman, J., Narayanan, V. L., Dykes, D., Szarvasi, E., Briet, P., Yoder, O. C., and Paull, K. D. Flavone acetic acid: A novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep., 70: 631-635, 1986.
3. O'Dwyer, P. J., Shoemaker, D., Zaharko, D. S., Grieshaber, C, Plowman, J., Corbett, T., Valeriote, F., King, S. A., Cradock, J., Hoth, D. F., and Leyland-Jones, B. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent. Cancer Chemother. Pharmacol., 19: 6-10, 1987.
4. Kerr, D. J., Kaye, S. B., Graham, J., Cassidy, J., Harding, M., Setanoians, A., McGrath, J.-C., Vezin, W. R., Cunningham, D., Forrest, G., and Soukop, M. Phase I and pharmacokinetic study of LM 985 (flavone acetic acid ester). Cancer Res., 46: 3142-3146, 1986.
5. Cummings, J., Smyth, J. F., Double, J. A., Farmer, P., and Kaye, S. B. Identification and characterization of the major human metabolites of flavone acetic acid (FAA). Proc. Am. Assoc. Cancer Res., 29: 486, 1988.
6. Knott, G. D. MLAB: A mathematical modelling tool. Comput. Programs Biomed., 10: 271-280, 1979.
7. Jongebreur, G. Relation between the chemical constitution and the pharma-cological action, especially on the coronary vessels of the heart, of some synthesized pyrones and khellin. Arch. Int. Pharmacodyn., 90: 384-411, 1952.
8. Corbett, T. H., Bissery, M.-C., Wozinak, A., Plowman, J., Polin, L., Tapa-Zoglou, E., Dieckman, J., and Valeriote, F. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest. New Drugs, 4: 207-220, 1986.
9. Drewinko, B., and Yang, L.-Y. The activity of flavone acetic acid (NSC 347512) on human colon cancer cells in vitro. Invest. New Drugs, 4: 289-293, 1986.
10. Bibby, M. C., Double, J. A., Phillips, R. M., and Loadman, P. M. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br. J. Cancer, 55: 159-163, 1987.
11. Wiltrout, R. H., Boyd, M. R., Back, T. T., Salup, R. R., Arthur, J. A., and Hornung, R. L. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J. Immunol., 140: 3261-3265, 1988.
12. Urba, W. J., Longo, D. L., Lombardo, F. A., and Weiss, R. B. Enhancement of natural killer cell activity in human peripheral blood by flavone acetic acid. J. Natl. Cancer Inst., 80: 521-525, 1988.
13. Kerr, D. J., Kaye, S. B., Cassidy, J., Bradley, C., Rankin, E. M., Adams, L., Setanoians, A., Young, T., Forrest, G., Soukop, M., and Clavel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res., 47: 6776-6781, 1987.